In Tuesday trading, Davita (DVA), a leading provider of dialysis services, and Berkshire Hathaway’s (BRK.B)16th-largest ...

Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces ...

DaVita HealthCare (DVA) closed the most recent trading day at $104.47, moving 5.11% from the previous trading session.

DAVID MICHAEL STAFFIERI, Chief Operating Officer at DaVita (NYSE:DVA), executed a substantial insider sell on August 19, according to an SEC filing. What Happened: STAFFIERI's decision to sell 42,119 ...

DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its ...

DaVita Inc . (NYSE: DVA), a leading provider of kidney care services, has reached an all-time high of $166.12, marking a significant milestone for the company's stock performance. This peak reflects a ...

After selling the DaVita Medical Group in 2019, DaVita focuses almost exclusively on providing services to end-stage renal disease, or ESRD, patients primarily in the United States with an expanding ...

The criminal trial of kidney care company DaVita Inc. and its former leader, Kent Thiry, ended its first week with a detailed look at the flow of DaVita employees to Radiology Partners, another health ...

Please provide your email address to receive an email when new articles are posted on . The price of DaVita stock plunged last week after the company reported a major drop in revenue in the third ...

Shares of DaVita Inc. plummeted in active trading Friday, to suffer their worst performance in more than two decades, after the dialysis company reported third-quarter that fell well below ...

Medtronic and DaVita Inc. are teaming up to create a new, independent company focused on kidney care. The new company will be owned equally by the two and led by an independent management team.